Scarborough Advisors’s LENZ Therapeutics LENZ Stock Holding History

Scarborough Advisors’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-80	Closed	-$732	–	730
2026 Q1	$732	Buy	+80	New	+$1.12K	﹤0.01%	657

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

7IH

72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Scarborough Advisors's LENZ Position: Q2 2026 in Review

Scarborough Advisors sold out of LENZ Therapeutics (LENZ) in Q2 2026, closing a stake of 80 shares — an estimated $732 sold.

Scarborough Advisors first reported a position in LENZ in Q1 2026 and held it in 1 quarter. The position peaked at $732 in Q1 2026. 145 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

Scarborough Advisors reported no remaining LENZ Therapeutics position as of Q2 2026 after selling out during the quarter.
Scarborough Advisors sold 80 LENZ Therapeutics shares in Q2 2026, an estimated $732.
Scarborough Advisors first reported a position in LENZ Therapeutics in Q1 2026 and held it in 1 quarter.
Scarborough Advisors's LENZ Therapeutics position peaked at $732 in Q1 2026.
145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Scarborough Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.